| Miramar Resources Limited (M2R) ORDINARY FULLY PAID |
Materials |
$3 |
Trading Halt
|
4 Dec 2025 9:08AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
M2R - Price-sensitive ASX Announcement
Full Release
Key Points
- Miramar Resources Limited (ASX: M2R) initiated a trading halt.
- The halt is to prevent uninformed trading and organize the market.
- A proposed capital raising through placement is pending announcement.
- The halt will last until the announcement or 8 December 2025 trading commencement.
- Miramar sees no reason against granting the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Golden Horse Minerals Limited (GHM) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$148 |
Application for quotation of securities - GHM
|
4 Dec 2025 9:08AM |
$0.815 |
$0.780 |
fallen by
4.29%
|
|
| Kogan.com Ltd (KGN) ORDINARY FULLY PAID |
Consumer Discretionary |
$334 |
Update - Notification of buy-back - KGN
|
4 Dec 2025 9:08AM |
$3.410 |
$3.340 |
fallen by
2.05%
|
|
| Larvotto Resources Limited (LRV) ORDINARY FULLY PAID |
Materials |
$603 |
Larvotto Acquires ECORE Technology for use at HIllgrove
|
4 Dec 2025 9:07AM |
$1.220 |
$1.165 |
fallen by
4.51%
|
|
LRV - Price-sensitive ASX Announcement
Full Release
Key Points
- Larvotto Resources Limited has acquired the ECORE core scanning system.
- The ECORE system is used at the Hillgrove Antimony-Gold Project in New South Wales.
- ECORE provides detailed quantitative mineralogy in near real-time.
- The technology supports exploration and metallurgical development activities.
- ECORE helps in geological logging, sample selection, and building a digital geological library.
- Larvotto aims to streamline decision-making processes and improve data-driven exploration.
- The technology assists in pre-feasibility and metallurgical testing, optimising grinding and liberation, and troubleshooting process control.
- Larvotto is positioning itself to be a significant producer of antimony, expecting to fulfill 7% of the global demand.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Indiana Resources Limited (IDA) ORDINARY FULLY PAID |
Materials |
$24 |
Notification regarding unquoted securities - IDA
|
4 Dec 2025 9:07AM |
$0.038 |
$0.037 |
fallen by
2.63%
|
|
| Connexion Mobility Ltd (CXZ) ORDINARY FULLY PAID |
Information Technology |
$22 |
Update - Notification of buy-back - CXZ
|
4 Dec 2025 9:06AM |
$0.026 |
$0.027 |
risen by
3.85%
|
|
| AdAlta Limited (1AD) ORDINARY FULLY PAID |
Health Care |
$8 |
Application for quotation of securities - 1AD
|
4 Dec 2025 9:06AM |
$0.003 |
$0.004 |
risen by
16.67%
|
|
| Regal Asian Investments Limited (RG8) ORDINARY FULLY PAID |
Financials |
$366 |
Update - Notification of buy-back - RG8
|
4 Dec 2025 9:05AM |
$2.470 |
$2.480 |
risen by
0.40%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$549 |
Update - Notification of buy-back - ACL
|
4 Dec 2025 9:05AM |
$2.800 |
$2.820 |
risen by
0.71%
|
|
| Regal Partners Global Investments Limited (RG1) ORDINARY FULLY PAID |
Financials |
$512 |
Update - Notification of buy-back - RG1
|
4 Dec 2025 9:04AM |
$2.120 |
$2.090 |
fallen by
1.42%
|
|
| Sunstone Metals Ltd (STM) ORDINARY FULLY PAID |
Materials |
$140 |
Trading Halt
|
4 Dec 2025 9:03AM |
$0.022 |
$0.022 |
fallen by
0%
|
|
STM - Price-sensitive ASX Announcement
Full Release
Key Points
- Sunstone Metals Ltd requested a trading halt.
- The trading halt is due to a pending announcement on a proposed capital raising.
- The halt is expected to last until 8 December 2025 or until the announcement is made.
- Sunstone Metals Ltd is not aware of any reason the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pacgold Limited (PGO) ORDINARY FULLY PAID |
Materials |
$25 |
Pacgold Completes White Dam Gold Project Acquisition
|
4 Dec 2025 9:01AM |
$0.061 |
$0.062 |
risen by
1.64%
|
|
PGO - Price-sensitive ASX Announcement
Full Release
Key Points
- Pacgold completes acquisition of White Dam Gold Operation.
- Acquisition includes 100% of Millstream Resources Pty Ltd.
- Total consideration: $1.2 million cash, 15 million shares, and a contingent $2.2 million.
- Strategic location near Broken Hill for gold and antimony exploration.
- Plans to restart production with a modest $600k capital expenditure.
- White Dam provides a pathway to near-term gold production.
- Project aligns with Pacgold's strategy for short-term cash flow.
- Phased plan for recommencing operations and exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ironbark Capital Limited (IBC) ORDINARY FULLY PAID |
Financials |
$45 |
Update - Notification of buy-back - IBC
|
4 Dec 2025 9:00AM |
$0.435 |
$0.435 |
fallen by
0%
|
|
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$12,839 |
Form 4 as filed - Bruce Brook
|
4 Dec 2025 8:56AM |
$137.510 |
$138.200 |
risen by
0.50%
|
|
| Cynata Therapeutics Limited (CYP) ORDINARY FULLY PAID |
Health Care |
$64 |
Positive DSMB Review in Phase 1/2 Kidney Transplant Trial
|
4 Dec 2025 8:56AM |
$0.250 |
$0.270 |
risen by
8%
|
|
CYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Independent DSMB review of trial Cohort 1 completed with no safety concerns.
- Clearance to proceed to Cohort 2 in Phase 1/2 kidney transplant trial.
- Demonstrates initial safety and tolerability of CYP-001 in kidney transplant recipients.
- Trial managed and funded by Leiden University Medical Centre.
- CYP-001 aims to address unmet need for safer therapies in kidney transplantation.
- No episodes of kidney transplant rejection in the first cohort.
- No serious adverse events or donor-specific antibodies detected.
- Positive outcome represents first step in clinical development program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Newmont Corporation (NEM) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$12,839 |
Statement of CDIs on issue - NEM
|
4 Dec 2025 8:55AM |
$137.510 |
$138.200 |
risen by
0.50%
|
|
| BlueScope Steel Limited (BSL) ORDINARY FULLY PAID |
Materials |
$10,430 |
Update - Notification of buy-back - BSL
|
4 Dec 2025 8:55AM |
$23.910 |
$23.780 |
fallen by
0.54%
|
|
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$53 |
Neurizon Completes GMP Tablet Registration Batches
|
4 Dec 2025 8:54AM |
$0.105 |
$0.100 |
fallen by
4.76%
|
|
NUZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Neurizon Therapeutics Limited completed manufacturing of three GMP registration batches of NUZ-001 tablets.
- The manufacturing was done in partnership with Catalent Inc., at a 1:10 scale of intended commercial production.
- The completion supports regulatory submissions with the FDA and potential commercial sales.
- NUZ-001 is developed for treating Amyotrophic Lateral Sclerosis (ALS).
- Neurizon is on track to commence enrollment in the HEALEY ALS Platform Trial in Q1 CY2026.
- The batches support long-term stability studies, NDA Module 3, and shelf-life validation.
- The company aims for global market access and long-term value creation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Woolworths Group Limited (WOW) ORDINARY FULLY PAID |
Consumer Staple |
$35,878 |
Moorebank Site Visit Presentation
|
4 Dec 2025 8:54AM |
$29.420 |
$29.370 |
fallen by
0.17%
|
|
| Morphic Ethical Equities Fund Limited (MEC) ORDINARY FULLY PAID |
Financials |
$36 |
Update - Notification of buy-back - MEC
|
4 Dec 2025 8:53AM |
$1.145 |
$1.140 |
fallen by
0.44%
|
|
| Australian United Investment Company Limited (AUI) ORDINARY FULLY PAID |
Financials |
$1,375 |
Update - Notification of buy-back - AUI
|
4 Dec 2025 8:49AM |
$11.040 |
$11.090 |
risen by
0.45%
|
|
| Vanadium Resources Limited (VR8) ORDINARY FULLY PAID |
Materials |
$18 |
Notification regarding unquoted securities - VR8
|
4 Dec 2025 8:48AM |
$0.025 |
$0.029 |
risen by
16%
|
|
| Diversified United Investment Limited (DUI) ORDINARY FULLY PAID |
Financials |
$1,140 |
Update - Notification of buy-back - DUI
|
4 Dec 2025 8:48AM |
$5.290 |
$5.310 |
risen by
0.38%
|
|
| Pengana Private Equity Trust (PE1) ORDINARY UNITS FULLY PAID |
Financials |
$349 |
Update - Notification of buy-back - PE1
|
4 Dec 2025 8:47AM |
$1.300 |
$1.295 |
fallen by
0.38%
|
|
| Harmoney Corp Limited (HMY) ORDINARY FULLY PAID |
Financials |
$91 |
Refinance of corporate debt with Big 4 Bank
|
4 Dec 2025 8:45AM |
$0.760 |
$0.875 |
risen by
15.13%
|
|
HMY - Price-sensitive ASX Announcement
Full Release
Key Points
- Execution of a $15 million revolving corporate debt facility with a Big-4 bank.
- Refinance of prior $22.5 million corporate debt at a lower margin.
- Repayment of $7.5 million of prior debt through surplus operating cash flows.
- The facility has a three-year term and market-standard financial covenants.
- Enhances Harmoney’s funding structure, adding to their $1 billion warehouse credit capacity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.